Nama Insights

Humana (HUM)

Healthcare · Healthcare Plans · NYSE

S&P 500
Humana (HUM) is a Healthcare company in the Healthcare Plans industry. It has a market capitalization of $45.64B, a trailing price-to-earnings ratio of 28.7 and a free-cash-flow yield of 0.8%. Over the most recent reported fiscal year, revenue grew 10.1% and free cash flow per share fell 84.3%. Nama's AI scorecard rates it Buy, 6.2 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Buy · 6.2/10
Positive, at the low end of Buy. As of Nov 20, 2026.
Momentum
Leading · +90.5% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-31.7%
How far the last close sits under the highest price of the past five years.
Market cap$45.64B
Trailing P/E28.7
Price / book2.4
Price / sales0.3
FCF yield0.8%
Dividend yield0.9%
Gross margin13.0%
Operating margin1.8%
Net margin0.8%
Revenue growth (YoY)+10.1%
Revenue growth (3-yr annual)+11.8%
EPS growth (YoY)+5.8%
FCF/share growth (YoY)-84.3%
Beta0.6
ExchangeNYSE
SectorHealthcare
IndustryHealthcare Plans

HUM earnings

Next report: Feb 10, 2027 (Q4 2026, EPS estimate -$7.55). Beat the EPS estimate in 4 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 6, 2026 -$0.70 -$1.00 +30.0% $41.16B
Q2 2026 Jul 29, 2026 $7.61 $7.00 +8.7% $40.87B
Q1 2026 Apr 29, 2026 $10.31 $10.20 +1.1% $39.65B
Q4 2025 Feb 11, 2026 -$3.96 -$3.99 +0.8% $32.52B

HUM analyst price target

Median target $518.00 from 24 analysts, ranging $280.00 – $602.00.

Healthcare Plans peers

TickerCompanyMarket capP/E
UNH UnitedHealth Group $296.12B 16.2
CVS CVS Health $102.41B 9.6
ELV Elevance Health $84.30B 12.9
CI Cigna Group $71.95B 8.6
CNC Centene $32.47B 12.4
MOH Molina Healthcare $10.61B 101.7
OSCR Oscar Health $8.13B 10.8
PGNY Progyny $2.61B 17.3
Explore live HUM data on Nama Insights →

Recent Congressional trades

Humana trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
Alan Armstrong Senate Buy $1,001 - $15,000 Jul 21, 2026
Gilbert Cisneros House Sell $1,001 - $15,000 Dec 15, 2025
Lisa McClain House Sell $1,001 - $15,000 Nov 21, 2025
Lisa McClain House Sell $1,001 - $15,000 Nov 21, 2025
Lisa McClain House Buy $1,001 - $15,000 Oct 22, 2025
Gilbert Cisneros House Buy $1,001 - $15,000 Sep 12, 2025
Lisa McClain House Buy $1,001 - $15,000 Aug 13, 2025
John James House Sell $1,001 - $15,000 Sep 6, 2024
John James House Buy $1,001 - $15,000 Sep 2, 2024

HUM FAQ

Is HUM a buy?
Nama's AI scorecard currently rates Humana Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is HUM's P/E ratio?
Humana trades at a trailing price-to-earnings ratio of 28.7.
When does HUM report earnings?
Humana's next scheduled report is on Feb 10, 2027. Analysts expect EPS of -$7.55.
What is the HUM price target?
The median analyst price target from 24 analysts is $518.00, with a range of $280.00 – $602.00.
Is HUM Shariah compliant?
Nama's AAOIFI-style screen reads Humana as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does HUM pay a dividend?
Yes — Humana's dividend yield is 0.9%.